We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-Ever Test of Cure for Chagas Disease Determines Treatment Effectiveness

By LabMedica International staff writers
Posted on 25 Jun 2025

An estimated 6 to 8 million individuals across the globe are infected with Trypanosoma cruzi, the parasite responsible for Chagas disease, which claims over 10,000 lives annually. More...

This disease doesn’t just affect humans; numerous mammals, including wildlife and domestic dogs, are also susceptible to infection. In current drug trials, clinicians can only determine when a treatment has failed. There remains a pressing need for a reliable test of cure—one that can confirm whether a drug has successfully eliminated the infection. A major challenge in confirming the effectiveness of treatment is that the immune system often keeps the infection under control, making parasite levels undetectable by existing tests due to their limited sensitivity. A new test protocol now offers the ability to detect low levels of T. cruzi, enabling accurate diagnosis in monkeys, dogs, and humans.

Researchers at the University of Georgia’s Center for Tropical and Emerging Global Diseases (Athens, GA, USA) performed extensive PCR testing on samples from naturally infected macaque monkeys, dogs, and humans. To improve detection, the team fragmented the DNA, helping it distribute more evenly within the sample—a step not included in standard PCR testing. The macaques, infected in a manner consistent with human and canine transmission, were monitored monthly over a year. A subset also underwent additional testing, with samples collected seven times in four weeks. Alongside PCR, researchers cultivated T. cruzi from blood samples, validating that the new protocol can detect infections even when parasite levels are extremely low. Given the similar disease progression in macaques, humans, and dogs, the researchers are confident that this method is broadly applicable across species.

Comparable results were observed when the protocol was applied to samples from naturally infected dogs and humans. The development of new drug treatments for Chagas disease is urgently needed, yet without an effective test of cure, researchers can only identify treatments that fail. Although the new protocol proves effective, it is also resource-intensive and time-consuming, making it expensive. To address this, the researchers explored technologies aimed at speeding up the process and reducing costs. They are currently developing a method that allows for the analysis of larger samples more quickly. Enhancing speed and cost-efficiency significantly increases the likelihood that the test can be adopted in clinical environments.

“This test of cure is a real game changer for drug treatment studies,” said Brooke White, lead researcher of the study. “We are already working with other research groups in hopes of creating a quicker and cheaper method of testing parasite load in their drug treatment studies in macaques, dogs and humans.”

Related Links:
Center for Tropical and Emerging Global Diseases


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.